lunes, 27 de octubre de 2014

NCTR Publications > NCTR Research Highlights

NCTR Publications > NCTR Research Highlights

National Center for Toxicological Researh log with FDA on left side

Current Highlight from October 24, 2014

Stem Cell Research
NCTR investigators made presentations to the Arkansas Stem Cell Coalition featuring work on 1) evaluating cardiotoxicity using induced pluripotent stem cells, 2) using mouse embryonic stem cells as an alternative model for developmental toxicity, 3) molecular networks examining the effects of fructose on adipocytes, and 4) the role of estrogen in mobilizing neural stem cells.
The Coalition is comprised of primary research scientists and clinicians who meet yearly to discuss results and future work ranging from basic biology, toxicology applications, regenerative medicine, and neural and cancer stem cells.  Plenary speakers this year were invited from Seattle, Los Angeles, Nashville, and Columbus. 
For additional information, please contact Deborah Hansen, Ph.D., Division of Systems Biology, FDA/NCTR.
Improving Neural Pathological Assessment Using MRI Targeting
Center for Drug Evaluation and Research and NCTR investigators used 10 classical neurotoxicants to test the ability of MRI technology to both detect and follow the course of events observed under traditional pathology evaluation.  The MRI can provide the equivalent of 64 planar “slices” of the brain (the estimated number for traditional neuropathology evaluation) “instantly” to the pathologist for targeting regions of interest for further evaluations.  The non-invasive MRI technology further permits each animal to be followed longitudinally to evaluate the inception, apex, and regression of lesions of interest.  Full-brain MRI imaging offers the potential to dramatically improve detection of neurotoxicity produced by new drugs and facilitate new drug development and evaluations. 
For additional information, the manuscript is available online at Regulatory Toxicology and Pharmacology or contact Joseph Hanig, Ph.D., FDA/CDER or Serguei Liachenko, Ph.D., Division of Neurotoxicology, FDA/NCTR.

Contact FDA

National Center for Toxicological Research
Food and Drug Administration
3900 NCTR Road
Jefferson, AR 72079

No hay comentarios:

Publicar un comentario